Literature DB >> 7149378

Studies on immunity to Haemophilus pleuropneumoniae infections in mice.

T N Sebunya, J R Saunders.   

Abstract

A murine model of experimentally induced Haemophilus pleuropneumoniae respiratory tract infections was developed and used to evaluate the efficacy of bacterins. Various doses of 3 H pleuropneumoniae strains (serotype 1 and 5) were administered intranasally (IN) to groups of anesthetized Swiss White mice. The accumulated mortality per group at 5 days after they were inoculated was used to calculate the median lethal dose (LD50), which ranged between 1.4 x 10(6) and 5.4 x 10(7) bacteria. There was correlation between dose administered, incubation period of the disease, and mortality. The induction of H pleuropneumoniae disease in the mouse was reproducible and resembled that of naturally occurring porcine Haemophilus pleuropneumonia. The murine model of exposure was used to evaluate the efficacy of H pleuropneumoniae serotype 5 (strain B78-3760) bacterins administered subcutaneously (SC) and IN. Vaccination by SC route induced slightly higher titers of specific seroagglutinins, compared with the response induced by the IN route, and the former was more effective in protecting mice against IN challenge with H pleuropneumoniae. However, vaccination was not efficacious in mice given a challenge dose greater than 1.2 LD50. The percentage survival rates in the SC and IN vaccinated mice were significantly greater than in the control groups at P less than 0.01 and P less than 0.05, respectively.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7149378

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  4 in total

1.  Resistance of C3H/HeJ mice to the effects of Haemophilus pleuropneumoniae.

Authors:  B W Fenwick; B I Osburn; H J Olander
Journal:  Infect Immun       Date:  1986-09       Impact factor: 3.441

2.  Virulence properties and protective efficacy of the capsular polymer of Haemophilus (Actinobacillus) pleuropneumoniae serotype 5.

Authors:  T J Inzana; J Ma; T Workman; R P Gogolewski; P Anderson
Journal:  Infect Immun       Date:  1988-08       Impact factor: 3.441

3.  Galactose-1-phosphate uridyltransferase (GalT), an in vivo-induced antigen of Actinobacillus pleuropneumoniae serovar 5b strain L20, provided immunoprotection against serovar 1 strain MS71.

Authors:  Fei Zhang; Qin Zhao; Keji Quan; Zhuang Zhu; Yusheng Yang; Xintian Wen; Yung-Fu Chang; Xiaobo Huang; Rui Wu; Yiping Wen; Qigui Yan; Yong Huang; Xiaoping Ma; Xinfeng Han; Sanjie Cao
Journal:  PLoS One       Date:  2018-06-01       Impact factor: 3.240

4.  Limited available evidence supports theoretical predictions of reduced vaccine efficacy at higher exposure dose.

Authors:  Kate E Langwig; M Gabriela M Gomes; Mercedes D Clark; Molly Kwitny; Steffany Yamada; Andrew R Wargo; Marc Lipsitch
Journal:  Sci Rep       Date:  2019-03-01       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.